E3 ubiquitin ligase RNF126 promotes cancer cell proliferation by targeting the tumor suppressor p21 for ubiquitin-mediated degradation

Cancer Research

Volumn 73, Issue 1, 2013, Pages 385-394

  Zhi, Xu ^a,c   Zhao, Dong ^a,c   Wang, Zehua ^a   Zhou, Zhongmei ^a   Wang, Chunyan ^a,b   Chen, Wenlin ^b   Liu, Rong ^a   Chen, Ceshi ^a  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

^b KUNMING MEDICAL UNIVERSITY   (China)

^c ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; MESSENGER RNA; PROTEIN P21; PROTEIN RNF126; SMALL INTERFERING RNA; SULFORHODAMINE B; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL LINE; CELL PROLIFERATION; CELL STRAIN MDA MB 231; CELL STRAIN PC3; CELL VIABILITY; CONTROLLED STUDY; EMBRYO; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN MICROARRAY; VALIDATION PROCESS;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; IMMUNOPRECIPITATION; MICE; MICE, SCID; NEOPLASMS; PROTEIN ARRAY ANALYSIS; TRANSPLANTATION, HETEROLOGOUS; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES;

EID: 84871989736     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-0562     Document Type: Article

References (36)

1. Ohta T, Fukuda M. Ubiquitin and breast cancer. Oncogene 2004;23:2079-88.
2. Ciechanover A, Iwai K. The ubiquitin system: from basic mechanisms to the patient bed. IUBMB Life 2004;56:193-201.
3. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-8.
4. Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A 2008;105:3933-8.
5. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009;458:732-6.
6. Soucy TA, Smith PG, Rolfe M. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res 2009;15:3912-6.
7. de Bie P, Ciechanover A. Ubiquitination of E3 ligases: self-regulation of the ubiquitin system via proteolytic and non-proteolytic mechanisms. Cell Death Differ 2011;18:1393-402.
8. Zheng M, Morgan-Lappe SE, Yang J, Bockbrader KM, Pamarthy D, Thomas D, et al. Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2. Cancer Res 2008;68:7570-8.
9. Burger A, Amemiya Y, Kitching R, Seth AK. Novel RING E3 ubiquitin ligases in breast cancer. Neoplasia 2006;8:689-95.
10. Burger AM, Gao Y, Amemiya Y, Kahn HJ, Kitching R, Yang Y, et al. A novel RING-type ubiquitin ligase breast cancer-associated gene 2 correlates with outcome in invasive breast cancer. Cancer Res 2005;65:10401-12.
11. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009;9:400-14.
12. Jung YS, Qian Y, Chen X. Examination of the expanding pathways for the regulation of p21 expression and activity. Cell Signal 2010;22:1003-12.
13. Yu ZK, Gervais JL, Zhang H. Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc Natl Acad Sci U S A 1998;95:11324-9.
14. Abbas T, Sivaprasad U, Terai K, Amador V, Pagano M, Dutta A. PCNA-dependent regulation of p21 ubiquitylation and degradation via the CRL4Cdt2 ubiquitin ligase complex. Genes Dev 2008;22:2496-506.
15. Amador V, Ge S, Santamaria PG, Guardavaccaro D, Pagano M. APC/C (Cdc20) controls the ubiquitin-mediated degradation of p21 in prometaphase. Mol Cell 2007;27:462-73.
16. Lee EW, Lee MS, Camus S, Ghim J, Yang MR, Oh W, et al. Differential regulation of p53 and p21 byMKRN1E3 ligase controls cell cycle arrest and apoptosis. EMBO J 2009;28:2100-13.
17. Nelson-Rees WA, Daniels DW, Flandermeyer RR. Cross-contamination of cells in culture. Science 1981;212:446-52.
18. Chen C, Seth AK, Aplin AE. Genetic and expression aberrations of e3 ubiquitin ligases in human breast cancer. Mol Cancer Res 2006;4:695-707.
19. Chen C, Zhou Z, Ross JS, Zhou W, Dong JT. Theamplified WWP1 gene is a potential molecular target in breast cancer. Int J Cancer 2007;121:2834-41.
20. Chen C, Sun X, Guo P, Dong XY, Sethi P, Cheng X, et al. Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells. J Biol Chem 2005;280:41553-61.
21. Li Y, Zhou Z, Chen C. WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis. Cell Death Differ 2008;15:1941-51.
22. Zhao D, Zheng HQ, Zhou Z, Chen C. The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation. Cancer Res 2010;70:4728-38.
23. Chen C, Benjamin MS, Sun X, Otto KB, Guo P, Dong XY, et al. KLF5 promotes cell proliferation and tumorigenesis through gene regulationin the TSU-Pr1 human bladder cancer cell line. Int J Cancer 2006;118:1346-55.
24. Di Fiore B, Pines J. Emi1 is needed to couple DNA replication with mitosis but does not regulate activation of the mitotic APC/C. J Cell Biol 2007;177:425-37.
25. Zhong Q, Chen Y, Jones D, Lee WH. Perturbation of TSG101 protein affects cell cycle progression. Cancer Res 1998;58:2699-702.
26. Bornstein G, Bloom J, Sitry-Shevah D, Nakayama K, Pagano M, Hershko A. Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J Biol Chem 2003;278:25752-7.
27. Nishitani H, Shiomi Y, Iida H, Michishita M, Takami T, Tsurimoto T.CDK inhibitor p21 is degraded by a proliferating cell nuclear antigen-coupled Cul4-DDB1Cdt2 pathway during S phase and after UV irradiation. J Biol Chem 2008;283:29045-52.
28. Lehner B, Semple JI, Brown SE, Counsell D, Campbell RD, Sanderson CM. Analysis of a high-throughput yeast two-hybrid systemand its use to predict the function of intracellular proteins encoded within the human MHC class III region. Genomics 2004;83:153-67.
29. Bouwmeester T, Bauch A, Ruffner H, Angrand PO, Bergamini G, Croughton K, et al. A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell Biol 2004;6:97-105.
30. Tsukahara T, Kimura S, Ichimiya S, Torigoe T, Kawaguchi S, Wada T, et al. Scythe/BAT3 regulates apoptotic cell death induced by papillomavirus binding factor in human osteosarcoma. Cancer Sci 2009;100:47-53.
31. Yamasaki S, Yagishita N, Nishioka K, Nakajima T. The roles of synoviolin in crosstalk between endoplasmic reticulum stress-induced apoptosis and p53 pathway. Cell Cycle 2007;6:1319-23.
32. Shmueli A, Tsai YC, Yang M, Braun MA, Weissman AM. Targeting of gp78 for ubiquitin-mediated proteasomal degradation by Hrd1: crosstalk between E3s in the endoplasmic reticulum. Biochem Biophys Res Commun 2009;390:758-62.
33. Kaulfuss S, Grzmil M, Hemmerlein B, Thelen P, Schweyer S, Neesen J, et al. Leupaxin, a novel coactivator of the androgen receptor, is expressed in prostate cancer and plays a role in adhesion and invasion of prostate carcinoma cells. Mol Endocrinol 2008;22:1606-21.
34. Kaulfuss S, von Hardenberg S, Schweyer S, Herr AM, Laccone F, Wolf S, et al. Leupaxin acts as a mediator in prostate carcinoma progression through deregulation of p120catenin expression. Oncogene 2009;28:3971-82.
35. Okumura F, Matsunaga Y, Katayama Y, Nakayama KI, Hatakeyama S. TRIM8 modulates STAT3 activity through negative regulation of PIAS3. J Cell Sci 2010;123:2238-45.
36. Li Q, Yan J,MaoAP, Li C, Ran Y, Shu HB, et al. Tripartite motif 8 (TRIM8) modulates TNFalpha- and IL-1beta-triggered NF-kappaB activation by targeting TAK1 for K63-linked polyubiquitination. Proc Natl Acad Sci U S A 2011;108:19341-6.